This trial will investigate whether pregabalin combined with lofexidine can reduce opioid withdrawal-related subjective effects and increase the proportion of patients with an opioid use disorder who complete detoxification and transition to antagonist treatment with extended-release injectable naltrexone.
1 Primary · 1 Secondary · Reporting Duration: 7 days
90 Total Participants · 2 Treatment Groups
Primary Treatment: PGB/LFX; · Has Placebo Group · Phase 2
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: